2-TOIFA QANDLI DIABET UCHUN SLGT2 PREPARATLARINI QO'LLASH SAMARADORLIGI
##article.subject##:
хроническая сердечная недостаточность, сахарный диабет II типа, SGLT2 терапия, дапаглифлозин##article.abstract##
SGLT2 blakatorlarining glyukazuriyalik tasirlari bilan yahwi havfsizlik profilining orqasida glyukoza miqdorini tuwiradigan dorilar sifatida birinchi aniqlandi.Keyin 2 tipli qant diabeti bilan ogriydigan bemorlarning yurak-qon tomiri va buyrak vazifasiga tegishli tasiri haqida tadqiqotlarining natijalari chiqa boshladi. Shu maqolamizda 2 tipli qant diabeti bilan ogriydigan bemorlarimizni davolashning natijalari aytiladi.
Библиографические ссылки
Michael E.N., Sheryl L.W., Barry A.В., Dalane K., Sanjiv J.S., Fengming T., et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial // Nat Med. – 2021. - №27(11). – Р. 1954-1960.
Scott D.S., Rudolf A., David D., Adrian F.H., Silvio E.I., Mikhail N.K., Carolyn S.P., et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial // Eur J Heart Fail. – 2021. - №23(7). – Р. 1217-1225.
Natalie A.M., Ify R.M., Jagdeep S.S., Rory J.M., Allan D.S., Chim C.L. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial // Circulation. - 2020. - №142(18). – Р.1713-1724.
Paul A.H.., Biykem B.., David A., Larry A.A., Joni J.B., Monica M.C., Anita D., Mark H.D., Shannon M.D., Linda R.E., James C.F., et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines // J Am Coll Cardiol. - 2022. - №79(17). – Р. 1757-1780.
Verma S., Mazer C.D., Yan A.T., Mason T., Garg V., Teoh H., Zuo F., Quan A., Farkouh M.E., Fitchett D.H., et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial // Circulation. – 2019. - №140. – Р.1693–1702.
Karin R., Gemma F., Vlado P., Scott D.S., Kenneth W.M., Dick de Z., Greg F., Terrance D.B., Wayne S., Mehul D., David R.M., Bruce N. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results from the CANVAS Program // Circulation // -2018. - №138(5). - Р. 458-468.
Wiviott S.D., Raz I., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A., Silverman M.G., Bansilal S., Bhatt D.L., Leiter L.A., et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial // Am Heart J. – 2018. -№200. -Р. 83–89.
Francesco C., Christopher P., David Z.I.C., Urszula M., Richard P., Sam D., Robert F., Bernard C., James M., Weichung J.S., Steven G.T., Nilo B.C., Ira G., Darren K.
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial // Circulation. – 2020. - №142(23). - Р. 2205-2215.
Invokana|European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/invokana (accessed on 31 August 2021).
Steglatro|European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/steglatro (accessed on 31 August 2021).
Jardiance|European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance (accessed on 31 August 2021).
Forxiga|European Medicines Agency. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga (accessed on 31 August 2021).
McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M., Burri H., Butler J., Čelutkienė J., Chioncel O., et al. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) with the Special Contribution of the Heart Failure Association (HFA) of the ESC // Eur. Heart J. – 2021. - №42. – Р. 3599–3726.
Gerber Y., Weston S.A., Redfield M.M., Chamberlain A.M., Manemann S.M., Jiang R., Killian J.M., Roger V.L. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010 // JAMA Intern Med. – 2015. - №175. – Р. 996–1004.
Tsao C.W., Lyass A., Enserro D., Larson M.G., Ho J.E., Kizer J.R., Gottdiener J.S., Psaty B.M., Vasan R.S. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction // JACC Heart Fail. – 2018. - №6. – Р. 678–685.
Dianna J. Magliano, Co-chair, Edward J. Boyko, Co-chair; IDF Diabetes Atlas 10th edition scientific committee. -2021. -Р.56-57;
